Taylor Harris

JPMorgan Securities LLC (JPMS) is a securities brokerage firm headquartered in New York City. The firm was founded in 1985 and is a subsidiary of JPMorgan Broker-Dealer Holdings, Inc., ultimately held by JPMorgan Chase & Co., Inc. (NYSE: JPM). JPMS provides research on fixed income, credit, derivatives, emerging markets, foreign exchange, structured finance, technical analysis and bond indices. Their equity analysts cover equities throughout North America, EMEA, Asia/Pacific and the emerging markets. The firm's fixed income team formulates trading and portfolio recommendations for investors in global bonds and other fixed-income markets based on valuations, analytics and market dynamics.

Thoratec Corp. develops, manufactures and markets proprietary medical devices used for circulatory support for the treatment of heart failure patients. The company's products include Ventricular Assist Devices, HeartMate Left Ventricular Assist System, HeartMate II Left Ventricular Assist System, Thoratec Paracorporeal Ventricular Assist Device and Thoratec Implantable Ventricular Assist. It also manufactures and markets the CentriMag Acute Circulatory System, HeartMate II, PVAD, IVAD and for pediatric patients PediMag/PediVAS Acute Circulatory System. Its ventricular assist devices products primarily serve patients suffering from late-stage heart failure. Heart Failure is a chronic disease that occurs when degeneration of the heart muscle reduces the pumping power of the heart, causing the heart to become too weak to pump blood at a level sufficient to meet the body's demands. The company operates its business through the Cardiovascular group segment, which develops, manufactures mechanical circulatory products to support the cardiovascular systems of humans and to provide product-related services. Thoratec was founded in March 1976 and is headquartered in Pleasanton, CA.

ZELTIQ Aesthetics, Inc. is a medical technology company, which focuses on developing and commercializing products. Its product, the coolsculpting system is designed to selectively reduce stubborn fat bulges. The company was founded by Mitchell E. Levinson in 2005 and is headquartered in North Chicago, IL.

MyoKardia, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, commercialization, and development of therapies for the treatment of cardiovascular diseases. Its lead therapeutic candidate, Mavacamten, is an orally administered allosteric modulator of cardiac myosin being developed for the treatment of hypertrophic cardiomyopathy (HCM). The company was founded by James A. Spudich, Jonathan G. Seidman, Christine Seidman, and Leslie Leinwand on June 8, 2012 and is headquartered in South San Francisco, CA.

HealthCor Catalio Acquisition Corp. operates as a Cayman Islands exempted company. It is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities. The company was founded on November 18, 2020 and is headquartered in New York, NY.

Endologix LLC engages in the research, development, manufacture, and trade of medical devices for the treatment of aortic disorders such as abdominal aortic aneurysms (AAA). Its products include AFX Endovascular AAA System, Nellix and Ovation. The company was founded in March 1992 and is headquartered in Irvine, CA.